Jynarque 45MG
Ended Awarded
- Contract number
- 36C24521F0222
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,304
Award facts
- Contract value 100% obligated
- $10,303.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Deerfield, IL 60015, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, through Veterans Integrated Service Network 5 (VISN 5), awarded a $10,303.55 delivery order to Otsuka America Pharmaceutical Inc. for Jynarque 45mg on February 5, 2021, with an ultimate completion date of February 10, 2021. This firm-fixed price delivery order, issued without a set-aside designation, was performed at the contractor's location in Riverwoods, Illinois. Jynarque (tolvaptan) is a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The delivery order was issued under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which establishes the terms and pricing for pharmaceutical procurement across VA facilities.
This delivery order is one of numerous task orders issued from Otsuka America Pharmaceutical Inc.'s larger Indefinite Delivery Vehicle with the VA—specifically an $83.3 billion Blanket Purchase Agreement awarded by the National Acquisition Center with an ultimate completion date of March 26, 2026. The company's established capacity to supply specialized pharmaceuticals to the VA's Veterans Health Administration across multiple VISNs demonstrates the critical role it plays in delivering essential medications to veterans nationwide. The firm-fixed price contracting approach reflects standard procurement practices for pharmaceutical products through the GSA schedule, ensuring predictable pricing and efficient delivery of this specialized therapeutic agent to VA medical facilities.
Quick answers
Who was awarded contract 36C24521F0222?
36C24521F0222 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 5, 2021.
How much is contract 36C24521F0222 worth?
The government has obligated $10,304 on 36C24521F0222.
Is contract 36C24521F0222 an order under another contract?
Yes. 36C24521F0222 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24521F0222 competed?
The extent of competition for 36C24521F0222 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award